A survey of people from 31 different countries around the world found that mental health was the biggest health problem respondents said was facing their country in 2024. Other health problems reported by respondents included cancer, stress, and obesity. The COVID-19 pandemic The COVID-19 pandemic impacted almost every country in the world and was the biggest global health crisis in recent history. It resulted in hundreds of millions of cases and millions of deaths, causing unprecedented disruption in health care systems. Lockdowns imposed in many countries to halt the spread of the virus also resulted in a rise of mental health issues as feelings of stress, isolation, and hopelessness arose. However, vaccines to combat the virus were developed at record speed, and many countries have now vaccinated large shares of their population. Nevertheless, in 2024, ** percent of respondents still stated that COVID-19 was the biggest health problem facing their country. Mental health issues One side effect of the COVID-19 pandemic has been a focus on mental health around the world. The two most common mental health issues worldwide are anxiety disorders and depression. In 2021, it was estimated that around *** percent of the global population had an anxiety disorder, while **** percent suffered from depression. Rates of depression are higher among females than males, with some *** percent of females suffering from depression, compared to *** percent of men. However, rates of suicide in most countries are higher among men than women. One positive outcome of the COVID-19 pandemic and the spotlight it shined on mental health may be a decrease in stigma surrounding mental health issues and seeking help for such issues. This would be a positive development as many people around the world do not or cannot receive the necessary treatment they need for their mental health.

In 2021, there were over ** million deaths from all types of cardiovascular diseases all over the world. This statistic describes the number of deaths caused by selected chronic diseases worldwide in 2021. Chronic disease has widespread consequences on both individuals, impacting both quality and length of life, as well as on societies and governments worldwide. Chronic disease The burden of chronic diseases, which is made up of the resulting disabilities and deaths, is increasing all over the globe. In 2022, lung cancer caused over *** million deaths worldwide, accounting for the highest number of cancer deaths. Furthermore, it is estimated that by 2045, there will be *** million people living with diabetes all over the globe. Although chronic diseases are not curable, their risk factors are highly preventable, usually through individual lifestyle and behavioral modifications. Public policies have been put into place in many countries worldwide to promote healthier lifestyles, for example by limiting the consumption of tobacco and alcohol. Impact on societies Chronic diseases can result in a heavy economic burden due to related health care costs and through the loss of workforce. Countries of all income statuses are affected by chronic diseases, with the leading causes of death in high-income countries from chronic disease. Moreover, the rising impact of chronic disease in low-income countries leads to a double burden, as they are forced to deal with both infectious diseases and non-communicable diseases. Weak health systems and poor economies often pose limits to these countries’ abilities to cope as well.

Since 2008, HIV/AIDS remains the most fatal infectious disease in China. In 2021, almost ** out of one million people in China died from AIDS. Tuberculosis stood at the second place, while rabies ranked the fourth.

Who are the high risk groups?

The HIV/AIDS epidemic has become a growing concern for the major population in China. A majority of new infections were the result from sexual transmission. Although the prevalence rate has been relatively low, the trend of new diagnoses in people aged from 15 to 24 years has been alarming, with gay men disproportionately represented.

Children under the age of ** are the most vulnerable group to contract common infectious diseases like influenza and HFMD. The Chinese government has thus introduced healthcare initiatives dedicated to vaccinating children up to the age of ** under the Extended Program for Immunization (EPI). The efforts have been fruitful with significant improvement in the healthcare status of children under the age of **** in the country.

How is disease controlled in China?

The world’s most populous nation has made considerable efforts in tracking and preventing the spread of infectious diseases. Alongside geographical and demographic challenges, the mortality rate of infectious diseases has seen a slight increase over the recent years. Seasonal diseases, especially Influenza and mumps, are easily widespread and have pressed the demand for efficient disease prevention and control. In response, the Chinese government has ramped up the supply of influenza vaccines and HPV vaccines.

What are people dying from?

This question is essential to guide decisions in public health, and find ways to save lives.

Many leading causes of death receive little mainstream attention. If news reports reflected what children died from, they would say that around 1,400 young children die from diarrheal diseases, 1,000 die from malaria, and 1,900 from respiratory infections – every day.

This can change. Over time, death rates from these causes have declined across the world.

A better understanding of the causes of death has led to the development of technologies, preventative measures, and better healthcare, reducing the chances of dying from a wide range of different causes, across all age groups.

In the past, infectious diseases dominated. But death rates from infectious diseases have fallen quickly – faster than other causes. This has led to a shift in the leading causes of death. Now, non-communicable diseases – such as heart diseases and cancers – are the most common causes of death globally.

More progress is possible, and the impact of causes of death can fall further.

On this page, you will find global data and research on leading causes of death and how they can be prevented.

This data can also help understand the burden of disease more broadly, and offer a lens to see the impacts of healthcare and medicine, habits and behaviours, environmental factors, health infrastructure, and more.

By Saloni Dattani, Fiona Spooner, Hannah Ritchie and Max Roser

IntroductionThe demographic shift leads to a tremendous increase in age-related diseases, which are often chronic. Therefore, a focus of chronic disease management should be set on the maintenance or even improvement of the patients’ quality of life (QoL). One indicator to objectively measure QoL is the EQ-5D questionnaire, which was validated in a disease- and world region-specific manner. The aim of this study was to conduct a systematic literature review and meta-analysis on the QoL across the most frequent chronic diseases that utilized the EQ-5D and performed a disease-specific meta-analysis for treatment-dependent QoL improvement.Materials and methodsThe most common chronic disease in Germany were identified by their ICD-10 codes, followed by a systematic literature review of these ICD-10 codes and the EQ-5D index values. Finally, out of 10,016 independently -screened studies by two persons, 538 studies were included in the systematic review and 216 studies in the meta-analysis, respectively.ResultsWe found significant medium to large effect sizes of treatment effects, i.e., effect size >0.5, in musculoskeletal conditions with the exception of fractures, for chronic depression and for stroke. The effect size did not differ significantly from zero for breast and lung cancer and were significantly negative for fractures.ConclusionOur analysis showed a large variation between baseline and post-treatment scores on the EQ-5D health index, depending on the health condition. We found large gains in health-related quality of life mainly for interventions for musculoskeletal disease.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020150936, PROSPERO identifier CRD42020150936.

Heart conditions were the most common causes of death in Mexico in 2023. During that period, more than ******* people died in the North American country as a result from said conditions. Diabetes mellitus ranked second, with over ******* deaths registered that year. Obesity in MexicoObesity and being overweight can worsen many risk factors for developing heart conditions, prediabetes, type 2 diabetes, and gestational diabetes, which in the case of a COVID-19 infection can lead to a severe course of the disease. In 2020, Mexico was reported as having one of the largest overweight and/or obese population in Latin America, with ** percent of people in the country having a body mass index higher than 25. In 2022, obesity was announced as being one of the most common illnesses experienced in Mexico, with over ******* cases estimated. In a decade from now, it is predicted that about *** million children in Mexico will suffer from obesity. If estimations are correct, this North American country will belong to the world’s top 10 countries with the most obese children in 2030. Physical activity in MexicoIt is not only a matter of food intake. A 2023 survey found, for instance, that only **** percent of Mexican population practiced sports and physical activities in their free time, a figure that has decreased in comparison to 2013. Less than ** percent of the physically active Mexicans practice sports for fun. However, the vast majority were motivated by health reasons.

It is estimated that around **** percent of the population in the United States has been diagnosed with an infectious disease. Infectious diseases are caused by bacteria, viruses and other organisms and can be spread from person to person, through insect or animal bites, or through contaminated food or water. Some of the most common infectious diseases include HIV/AIDS, influenza, malaria, tuberculosis and hepatitis.

HIV/AIDS

HIV/AIDS is one of the most well-known infectious diseases worldwide. There are currently almost ** million people worldwide living with HIV and it is responsible for just under a million deaths per year. HIV treatment has improved dramatically over the last few decades but access to treatment varies. The poorer regions of the world still suffer disproportionately from HIV with the majority of those infected living in Africa.

Tuberculosis

Like HIV/AIDS, tuberculosis also impacts the poorer regions of the world more than developed nations. Tuberculosis impacts the lungs of those infected and is currently the tenth leading cause of death worldwide. The countries with the highest incidence rates of tuberculosis include India, China, Indonesia, and the Philippines. In India alone tuberculosis was responsible for around ******* deaths in 2018.

The deadliest animals in the world based on the number of human deaths per year is not a creature that humans usually find scary, such as a lion or snake. Mosquitos are by far the deadliest creature in the world when it comes to annual human deaths, causing around one million deaths per year, compared to 100,000 deaths from snakes and 250 from lions. Perhaps surpringly, dogs are the third deadliest animal to humans. Dogs are responsible for around 30,000 human deaths per year, with the vast majority of these deaths resulting from rabies that is transmitted from the dog. Malaria
Mosquitos are the deadliest creature in the world because they transmit a number of deadly diseases, the worst of which is malaria. Malaria is a mosquito-borne disease caused by a parasite that results in fever, chills, headache, vomiting and, if left untreated, death. Malaria disproportionately affects poorer regions of the world such as Africa and South-East Asia. In 2020, there were around 627,000 deaths from malaria worldwide. Mosquito-borne diseases in the U.S.
The most common mosquito-borne diseases reported in the United States include West Nile virus, malaria, and dengue viruses. Many of these cases, however, are from travelers who contracted the disease in another country - this is especially true for malaria, Zika, and dengue. In 2018, the states of California, New York, and Texas reported the highest number of mosquito-borne disease cases in the United States.

JP: Prevalence of Severe Wasting: Weight for Height: Male: % of Children under 5 data was reported at 0.300 % in 2010. JP: Prevalence of Severe Wasting: Weight for Height: Male: % of Children under 5 data is updated yearly, averaging 0.300 % from Dec 2010 (Median) to 2010, with 1 observations. JP: Prevalence of Severe Wasting: Weight for Height: Male: % of Children under 5 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank: Health Statistics. Prevalence of severe wasting, male, is the proportion of boys under age 5 whose weight for height is more than three standard deviations below the median for the international reference population ages 0-59.; ; World Health Organization, Global Database on Child Growth and Malnutrition. Country-level data are unadjusted data from national surveys, and thus may not be comparable across countries.; Linear mixed-effect model estimates; Undernourished children have lower resistance to infection and are more likely to die from common childhood ailments such as diarrheal diseases and respiratory infections. Frequent illness saps the nutritional status of those who survive, locking them into a vicious cycle of recurring sickness and faltering growth (UNICEF, www.childinfo.org). Estimates of child malnutrition, based on prevalence of underweight and stunting, are from national survey data. The proportion of underweight children is the most common malnutrition indicator. Being even mildly underweight increases the risk of death and inhibits cognitive development in children. And it perpetuates the problem across generations, as malnourished women are more likely to have low-birth-weight babies. Stunting, or being below median height for age, is often used as a proxy for multifaceted deprivation and as an indicator of long-term changes in malnutrition.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had been confirmed in almost every country in the world. The virus had infected over 687 million people worldwide, and the number of deaths had reached almost 6.87 million. The most severely affected countries include the U.S., India, and Brazil.

COVID-19: background information COVID-19 is a novel coronavirus that had not previously been identified in humans. The first case was detected in the Hubei province of China at the end of December 2019. The virus is highly transmissible and coughing and sneezing are the most common forms of transmission, which is similar to the outbreak of the SARS coronavirus that began in 2002 and was thought to have spread via cough and sneeze droplets expelled into the air by infected persons.

Naming the coronavirus disease Coronaviruses are a group of viruses that can be transmitted between animals and people, causing illnesses that may range from the common cold to more severe respiratory syndromes. In February 2020, the International Committee on Taxonomy of Viruses and the World Health Organization announced official names for both the virus and the disease it causes: SARS-CoV-2 and COVID-19, respectively. The name of the disease is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged.

Snapshot img

Non-Cancerous Skin Diseases Therapeutics Market Size 2025-2029

The non-cancerous skin diseases therapeutics market size is forecast to increase by USD 31.46 billion at a CAGR of 11.1% between 2024 and 2029.

The market is witnessing significant growth, driven primarily by the high prevalence of skin diseases worldwide. According to the World Health Organization, over 3,000 types of skin conditions exist, affecting millions of people globally. This substantial patient population creates a substantial market opportunity for therapeutic solutions. Another key trend in the market is the increased focus on microbiome and skin barrier research. The microbiome, the collection of microorganisms that inhabit the skin, plays a crucial role in maintaining skin health. Understanding the intricacies of the microbiome and its interaction with the skin barrier can lead to the development of novel therapeutic approaches for various skin conditions.
Additionally, the growing awareness of the importance of maintaining a healthy skin microbiome and barrier is fueling demand for such treatments. However, the market also faces challenges, including increasing generic competition. As more generic alternatives enter the market, pricing pressures intensify, making it challenging for market players to maintain profitability. This competition is particularly pronounced in mature markets, where many skin conditions have well-established treatments. Companies seeking to capitalize on market opportunities and navigate challenges effectively must focus on innovation, differentiation, and strategic pricing to stay competitive.

What will be the Size of the Non-Cancerous Skin Diseases Therapeutics Market during the forecast period?

Request Free Sample

The market continues to evolve, driven by the ongoing development of innovative treatments and technologies. Inflammation reduction and skin cancer prevention remain key focus areas, with a growing emphasis on personalized therapies and targeted treatments. Drug development is accelerated through the integration of artificial intelligence and machine learning, enabling the analysis of large datasets and the identification of new therapeutic targets. Genetic testing and personalized medicine are also transforming the landscape, allowing for more effective treatment plans based on individual genetic profiles. Topical treatments, including those that address the skin microbiome and promote skin barrier repair, are gaining popularity.
Healthcare providers and clinical trials are collaborating to improve patient outcomes and increase access to care. Environmental factors and lifestyle modifications continue to be important considerations in disease management, with a growing focus on sun protection and patient education. Oral medications, itch relief, and quality of life are also priorities, with a growing emphasis on Precision Medicine and regenerative approaches, including Stem Cell Therapy and gene editing. Big data analytics and skin care are also playing increasingly important roles in the market, with a focus on skin hydration, microbiome analysis, and patient access. The market's continuous dynamism reflects the ongoing efforts to address the diverse needs of patients with non-cancerous skin diseases.

How is this Non-Cancerous Skin Diseases Therapeutics Industry segmented?

The non-cancerous skin diseases therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Therapy Area

  Psoriasis
  Eczema
  Acne vulgaris
  Others


Route Of Administration

  Injectable
  Oral
  Topical


End-user

  Hospitals
  Dermatology Clinics
  Homecare


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  Middle East and Africa

    South Africa


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Therapy Area Insights

The psoriasis segment is estimated to witness significant growth during the forecast period.

Non-cancerous skin diseases, including psoriasis, pose a significant health challenge for millions worldwide. Psoriasis, a chronic and painful condition affecting over 125 million people, accelerates the lifestyle of skin cells, resulting in scales and red patches. Its immune system abnormalities can also impact Mental Health and lead to comorbidities like cardiovascular diseases and diabetes. In the US, plaque psoriasis, the most common type, affects approximately 8 million people, according to the American Academy of Dermatology (AAD). Digital Health solutions, such as mobile applications and remote monitoring, are increasingly being employed to manage these conditions. Patient education and disease management are crucial aspects of care, with d

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Fever is one of the most basic and pervasive of human experiences. While fever is in some measure a universal feature of humans’ material existence, however, its relevance and meaning, its sensory experience and implications, differed from one historical context to another. This ERC project studies fever globally, particularly in societies within or tied to the Atlantic world, in the century spanning from the 1750s to the 1840s – a time when fever was not only considered the most common ailment that afflicted mankind, but also its most fatal one; ‘more persons died of fever than of all other ailments combined’, as contemporaries saw it. Given that fever was a threatening, ubiquitous presence for men and women around 1800, we know surprisingly little about it; as one medical historian recently put it, ‘fever has been the invisible elephant in the china shop of the medical past’. Premised upon archival research in countries across the world, the FEVER project studies various aspects of the history of fever around 1800, such as: the unusual prevalence of fevers in the period’s medical record; the period’s means of diagnosis, especially pulse diagnosis, in a period prior to the advent of thermometry; the role of emotions as both causes and symptoms of fever; ‘obstinate’, chronic, relapsing or seasonal fevers and their long-term consequences; vernacular and non-European fever remedies; and fever’s resonance and relation with similar or affine disease concepts in other, non-European empires. The project poses questions fundamental to our understanding of both the past and the present: about the rise and fall of diseases, the credibility of medical knowledge, and how cultural and historical contexts affect suffering and physiology, and vice versa.

Congenital Heart Disease Occluder Market Outlook

As of 2023, the global congenital heart disease occluder market size is estimated to be worth approximately $1.2 billion, with projections indicating growth to $2.5 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 8.5%. This significant market expansion is underpinned by technological advancements in medical devices, increasing prevalence of congenital heart anomalies, and growing awareness regarding minimally invasive treatment options. Factors such as the rising incidence of congenital heart defects, improvements in healthcare infrastructure, and increasing healthcare expenditure are also pivotal in driving the market's growth trajectory.

One of the primary growth factors of the congenital heart disease occluder market is the technological innovation that continues to enhance the safety and efficacy of occluder devices. Advances in materials science and medical engineering have enabled the development of occluders that offer improved biocompatibility, reducing the risk of adverse reactions and enhancing patient outcomes. These innovations make procedures less invasive, thereby shortening recovery times and hospital stays, which is a significant consideration for both patients and healthcare providers. In addition, the integration of imaging technologies, such as 3D echocardiography and MRI, has improved the precision of congenital heart defect diagnosis, facilitating the selection of the most appropriate occluder device for each patient and boosting demand for such advanced medical solutions.

Another key growth factor is the increasing prevalence and diagnosis of congenital heart defects (CHDs) worldwide. Congenital heart defects are among the most common birth defects, impacting thousands of infants annually. Advances in diagnostic techniques have not only led to early detection of such conditions but have also improved our understanding of the epidemiology of CHDs. This heightened awareness and the corresponding increase in the patient population drive the demand for effective CHD management solutions like occluder devices. Furthermore, educational initiatives and campaigns aimed at raising awareness about CHDs among healthcare professionals and patients are contributing to increased diagnosis and treatment uptake, thereby propelling market growth.

Demographic factors also play a critical role in the growth of the congenital heart disease occluder market. The pediatric population, which is primarily affected by congenital heart anomalies, is growing in many parts of the world. In addition, as healthcare access improves in emerging economies, more pediatric and adult patients with untreated or previously undiagnosed CHDs are entering the healthcare system. The geriatric population, often requiring secondary intervention due to a history of untreated CHDs, also represents a growing segment contributing to the market demand. Collectively, these demographic trends underscore the growing need for occluder devices across different patient age groups, further amplifying market growth.

Regionally, North America holds a significant share of the congenital heart disease occluder market, largely due to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development activities. In contrast, the Asia Pacific region is anticipated to exhibit the fastest growth rate over the forecast period. This growth is attributed to improving healthcare facilities, a large patient base, and increasing public and private sector investments in healthcare. Moreover, rising awareness and government initiatives aimed at improving pediatric care in emerging economies such as China and India are expected to contribute significantly to the regional market expansion. Meanwhile, Europe continues to be a key market, driven by high awareness levels, well-established healthcare systems, and favorable government policies supporting medical device innovation.

The introduction of the Atrial Appendage Occluder has been a significant advancement in the field of congenital heart disease treatment. This device is designed to prevent blood clots from forming in the atrial appendage, a small pouch in the heart that can be a source of clot-related complications such as stroke. By occluding the atrial appendage, the device reduces the risk of these complications, offering a minimally invasive solution that enhances patient safety and outcomes. The development of the Atrial Appendage Occluder reflects the ongoing innovation in cardi

JP: Mortality Rate: Under-5: Male: per 1000 Live Births data was reported at 2.700 Ratio in 2017. This records a decrease from the previous number of 3.200 Ratio for 2015. JP: Mortality Rate: Under-5: Male: per 1000 Live Births data is updated yearly, averaging 3.400 Ratio from Dec 1990 (Median) to 2017, with 5 observations. The data reached an all-time high of 6.900 Ratio in 1990 and a record low of 2.700 Ratio in 2017. JP: Mortality Rate: Under-5: Male: per 1000 Live Births data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank: Health Statistics. Under-five mortality rate, male is the probability per 1,000 that a newborn male baby will die before reaching age five, if subject to male age-specific mortality rates of the specified year.; ; Estimates Developed by the UN Inter-agency Group for Child Mortality Estimation (UNICEF, WHO, World Bank, UN DESA Population Division) at www.childmortality.org.; Weighted average; Given that data on the incidence and prevalence of diseases are frequently unavailable, mortality rates are often used to identify vulnerable populations. Moreover, they are among the indicators most frequently used to compare socioeconomic development across countries. Under-five mortality rates are higher for boys than for girls in countries in which parental gender preferences are insignificant. Under-five mortality captures the effect of gender discrimination better than infant mortality does, as malnutrition and medical interventions have more significant impacts to this age group. Where female under-five mortality is higher, girls are likely to have less access to resources than boys.

Chronic Respiratory Diseases Treatment Market Outlook

According to our latest research, the global chronic respiratory diseases treatment market size reached USD 56.2 billion in 2024, reflecting robust demand for effective therapies and interventions worldwide. The market is expected to register a steady CAGR of 5.8% from 2025 to 2033, with the total market value forecasted to reach USD 93.4 billion by 2033. This growth is primarily driven by the increasing prevalence of chronic respiratory diseases, rising geriatric population, and continuous advancements in therapeutic modalities.

A significant growth factor for the chronic respiratory diseases treatment market is the surging incidence of chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. According to the World Health Organization, over 262 million people were affected by asthma and more than 3 million deaths were attributed to COPD in recent years. Urbanization, exposure to pollutants, and tobacco use have further elevated the risk, making chronic respiratory diseases a leading cause of morbidity and mortality globally. This epidemiological trend is compelling healthcare systems to invest in advanced diagnostics, personalized medicines, and integrated care models, thereby fueling the demand for chronic respiratory disease treatments.

Another crucial driver is the ongoing innovation in treatment modalities and drug development. Pharmaceutical companies are increasingly focusing on developing novel bronchodilators, biologics, and combination therapies that offer improved efficacy and safety profiles. The emergence of digital health technologies and telemedicine has also transformed disease management, enabling remote monitoring, early intervention, and better patient adherence. These technological advancements, coupled with increased awareness and screening programs, are ensuring timely diagnosis and effective management of chronic respiratory diseases, further propelling market growth.

The aging population is another pivotal factor influencing the chronic respiratory diseases treatment market. As the global demographic shifts towards an older population, the burden of chronic diseases, particularly respiratory ailments, is expected to rise. Elderly individuals are more susceptible to respiratory infections and are at higher risk of developing complications from chronic conditions. This demographic trend is prompting healthcare providers to adopt multidisciplinary approaches, integrating pharmacological treatments with pulmonary rehabilitation, oxygen therapy, and lifestyle interventions to enhance patient outcomes and quality of life.

Regionally, North America continues to dominate the market, attributed to its advanced healthcare infrastructure, high disease awareness, and robust reimbursement policies. However, Asia Pacific is rapidly emerging as a lucrative market, driven by increasing healthcare expenditure, rising pollution levels, and a growing patient pool. Europe also holds a significant share, supported by government initiatives and strong research activities in respiratory medicine. Latin America and the Middle East & Africa are witnessing gradual growth, fueled by improving access to healthcare and expanding pharmaceutical distribution networks.

Disease Type Analysis

The disease type segment of the chronic respiratory diseases treatment market encompasses asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, occupational lung diseases, and other less common respiratory disorders. Asthma remains one of the most prevalent conditions, accounting for a substantial portion of the market share. The increasing incidence of allergic reactions, environmental triggers, and genetic predispositions are contributing to the growing patient base. The availability of advanced inhalation therapies, biologics, and patient education programs has significantly improved asthma manageme

Lysosomal Storage Diseases Market Outlook

The global lysosomal storage diseases (LSDs) market size was valued at approximately USD 7.5 billion in 2023 and is expected to reach USD 14.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. This anticipated growth is driven by several pivotal factors, including advancements in therapeutic methods, increased awareness, and improved diagnostic capabilities. The increasing incidence of lysosomal storage diseases due to genetic predisposition and mutations, coupled with the emergence of more effective treatment modalities, is propelling the market forward. Furthermore, significant investments in research and development by pharmaceutical companies and government initiatives to increase awareness about rare diseases are expected to fuel market growth.

One major growth factor for the lysosomal storage diseases market is the rapid advancement in biotechnology and genetic engineering, leading to innovative treatment solutions. Enzyme Replacement Therapy (ERT) is the most common treatment for LSDs and continues to evolve, providing improved outcomes and reduced side effects. This has increased the adoption of ERT, particularly among healthcare providers who manage LSD patients. Furthermore, the development of Substrate Reduction Therapy (SRT) offers an alternative for patients who cannot tolerate ERT, showcasing a significant step forward in personalized medicine. These therapeutic advancements, combined with ongoing clinical trials exploring gene therapy and stem cell treatments, are creating a more robust and versatile treatment landscape for LSDs.

Another crucial growth factor is the increasing awareness and understanding of lysosomal storage diseases among healthcare professionals and the general public. The complexity and rarity of LSDs have historically limited diagnosis and treatment options. However, awareness campaigns and educational programs have played a significant role in improving the recognition and diagnosis of these diseases. As a result, there is a growing demand for early screening and intervention, which has led to an increase in diagnostic testing and subsequent treatment. Furthermore, patient advocacy groups have been instrumental in lobbying for better healthcare policies and funding for LSD research, thus driving market growth.

Additionally, the growing prevalence of LSDs globally, driven by genetic and environmental factors, significantly contributes to market expansion. Increased genetic screening and improved diagnostic technologies have resulted in higher reported cases, especially in regions where these diseases were previously underdiagnosed. With a better understanding of the genetic basis of LSDs, there is an increased focus on newborn screening programs which enable early detection and management of these conditions. These initiatives are expected to increase patient numbers undergoing treatment, further supporting market growth over the forecast period.

Lou Gehrigs Disease, also known as Amyotrophic Lateral Sclerosis (ALS), is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. While it is not classified under lysosomal storage diseases, the research advancements in genetic therapies for LSDs have provided insights that could be beneficial in understanding and potentially treating ALS. The focus on genetic mutations and enzyme deficiencies in LSDs parallels the efforts to identify genetic markers and therapeutic targets in ALS, highlighting the interconnected nature of rare disease research. As the medical community continues to explore these links, there is hope for breakthroughs that could impact both fields.

Regionally, the North American lysosomal storage diseases market holds a significant share, driven by advanced healthcare infrastructure, high awareness levels, and substantial investment in research and development. Europe follows closely, benefiting from strong pharmaceutical industry presence and supportive regulatory frameworks. However, the Asia Pacific region is expected to witness the fastest growth rate due to rising healthcare expenditures, increased awareness, and government initiatives to improve healthcare access for rare diseases. Latin America and the Middle East & Africa regions are also experiencing growth, albeit at a slower pace, as efforts to improve healthcare systems and awareness programs begin to take effect.

Treatment Type Analysis

In the lysosomal s

Background: In 2019, 80% of the 7.4 million global child deaths occurred in low- and middle-income countries (LMICs). Global and regional estimates of cause of hospital death and admission in LMIC children are needed to guide global and local priority setting and resource allocation but are currently lacking. The study objective was to estimate global and regional prevalence for common causes of pediatric hospital mortality and admission in LMICs. Methods: We performed a systematic review and meta-analysis to identify LMIC observational studies published January 1, 2005-February 26, 2021. Eligible studies included: a general pediatric admission population, a cause of admission or death, and total admissions. We excluded studies with data before 2000 or without a full text. Two authors independently screened and extracted data. We performed methodological assessment using domains adapted from the Quality in Prognosis Studies tool. Data were pooled using random-effects models where possible. We reported prevalence as a proportion of cause of death or admission per 1000 admissions with 95% confidence intervals (95%CI). Findings: ur search identified 29,637 texts. After duplicate removal and screening, we analyzed 253 studies representing 21.8 million pediatric hospitalizations in 59 LMICs. All-cause pediatric hospital mortality was 4.1% [95%CI 3.4-4.7%]. The most common causes of mortality (deaths/1000 admissions) were infectious (12 [95%CI 9-14]); respiratory (9 [95%CI 5-13]); and gastrointestinal (9 [95%CI 6-11]). Common causes of admission (cases/1000 admissions) were respiratory (255 [95%CI 231-280]); infectious (214 [95%CI193-234]); and gastrointestinal (166 [95%CI 143-190]). We observed regional variation in estimates. Pediatric hospital mortality remains high in LMICs. Implications: Global child health efforts must include measures to reduce hospital mortality including basic emergency and critical care services tailored to the local disease burden. Resources are urgently needed to promote equity in child health research, support researchers, and collect high-quality data in LMICs to further guide priority setting and resource allocation. NOTE for restricted files: If you are not yet a CoLab member, please complete our membership application survey to gain access to restricted files within 2 business days. Some files may remain restricted to CoLab members. These files are deemed more sensitive by the file owner and are meant to be shared on a case-by-case basis. Please contact the CoLab coordinator at sepsiscolab@bcchr.ca or visit our website.

Context

In 2010, the UN General Assembly recognized access to safe and clean drinking water and sanitation as a human right, and called for international efforts to help countries to provide safe, clean, accessible and affordable drinking water and sanitation. Sustainable Development Goal target 6.2 calls for adequate and equitable sanitation for all. The target is tracked with the indicator of “safely managed sanitation services” – use of an improved type of sanitation facility that is not shared with other households and from which the excreta produced are either safely treated in situ, or transported and treated off-site.

Some 827 000 people in low- and middle-income countries die as a result of inadequate water, sanitation, and hygiene each year, representing 60% of total diarrhoeal deaths. Poor sanitation is believed to be the main cause in some 432 000 of these deaths.

Diarrhea remains a major killer but is largely preventable. Better water, sanitation, and hygiene could prevent the deaths of 297 000 children aged under 5 years each year.

Open defecation perpetuates a vicious cycle of disease and poverty. The countries where open defection is most widespread have the highest number of deaths of children aged under 5 years as well as the highest levels of malnutrition and poverty, and big disparities of wealth.

Inspiration

Given the importance of sanitation in the spread of a disease, we need to make sure everyone has access to proper measures required. Different countries have different facilities and policies regarding the same. We can answer questions pertaining to the issue - which country has the least hygienic measures? which country has faced major diseases due to inadequate facilities? etc.

Feel free to answer your questions based on the research. I hope you find answers of relevance.

Snapshot img

Gastrointestinal Diseases Therapeutics Market Size 2025-2029

The gastrointestinal diseases therapeutics market size is forecast to increase by USD 20.68 billion at a CAGR of 7.1% between 2024 and 2029.

The market is witnessing significant growth due to the rising incidence of gastrointestinal diseases. This trend is driven by various factors, including an aging population, unhealthy lifestyle choices, and increasing awareness and diagnosis of gastrointestinal disorders. The Simethicone market is also growing due to its effectiveness in treating symptoms of GERD, such as bloating and burping. A key trend in the market is the availability of nutritional therapies, which offer an alternative treatment approach for managing gastrointestinal diseases. However, the high cost of gastrointestinal therapeutics poses a significant challenge for both patients and healthcare systems. This challenge is compounded by the complex nature of these diseases, which often require long-term treatment and frequent monitoring.
Additionally, investments in research and development of targeted therapies and personalized medicine approaches could help address the unmet needs of patients and improve treatment outcomes. Over-the-counter (OTC) drugs, including anti-emetics and laxative preparations, are also part of the market landscape. Overall, the market holds immense potential for innovation and growth, with opportunities for companies to differentiate themselves through cost-effective solutions, targeted therapies, and strategic partnerships. To capitalize on market opportunities, companies must focus on developing cost-effective therapies and exploring partnerships with payers and healthcare providers to improve patient access.

What will be the Size of the Gastrointestinal Diseases Therapeutics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market encompasses a diverse range of conditions, including Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroesophageal reflux disease, inflammatory bowel disease, gastrointestinal cancers, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and other chronic digestive disorders. Novel therapies are gaining traction in this market, with a focus on targeted drugs that address the underlying causes of these autoimmune diseases. Gi drugs are increasingly being developed to provide more effective and personalized treatment options. The market is driven by the growing prevalence of these conditions and the unmet medical needs of patients. Gastrointestinal disorders impact millions of individuals worldwide, leading to significant morbidity and mortality.
The development of new therapies and treatments is crucial to improving patient outcomes and reducing the burden on healthcare systems. Inflammatory bowel disease, for instance, affects over 3 million Americans, with Crohn's disease and ulcerative colitis being the most common forms. The market for gi drugs is expected to grow at a steady pace, driven by the increasing prevalence of these conditions and the development of new, targeted therapies. Gastrointestinal cancers, such as colorectal cancer, are another significant area of focus, with ongoing research into new treatments and therapies. The use of biologics and targeted drugs in the treatment of gastrointestinal disorders is becoming increasingly common, offering more effective and personalized treatment options for patients.

How is this Gastrointestinal Diseases Therapeutics Industry segmented?

The gastrointestinal diseases therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Anti-inflammatory
  Acid neutralizers
  Others


Type

  Branded
  Generics


Route Of Administration

  Parenteral
  Oral
  Rectal


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The anti-inflammatory segment is estimated to witness significant growth during the forecast period. The market encompasses various segments addressing a spectrum of conditions, including inflammatory bowel diseases (IBD), gastroesophageal reflux disease (GERD), gastrointestinal cancers, and chronic digestive diseases. IBD, such as Crohn's disease and ulcerative colitis, necessitate anti-inflammatory treatments. This segment's growth is driven by the escalating prevalence of these diseases, the increasing focus on biologics development, and promising treatment outcomes. TNF blockers, injectable anti-inflammatory